FDA Brief

Company record

Regeneron Pharmaceuticals Inc

0 FDA warning letters since 2023 and 1 recall in the last 12 months.

Get an email the day FDA posts anything new about Regeneron Pharmaceuticals Inc.

Recalls

ReportedClassFirmProduct and reason
Aug 26 Class II Regeneron Pharmaceuticals Inc
Drug
Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regener…
Lack of Assurance of Sterility